Merbromin
drug drugOn this page
Also known as Merbromin sodiumMerbrominaMerbromineMercurochromeNSC-757381
Summary
Merbromin (CHEMBL3833381) is an approved small molecule (ATC D08AK04).
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D08AK04
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3833381 |
| Name | Merbromin |
| Type | Small molecule |
| Max phase | 4 |
| ATC | D08AK04 |
Also known as: Merbromin, Merbromin sodium, Merbromina, Merbromine, Mercurochrome, NSC-757381, MERBROMIN
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Replicase polyprotein 1ab.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P0DTD1 | 6.62 | IC50 | 240 | nM | CHEMBL_ACT_19964262 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.